A safety review board has recommended that regulators allow Pharnext to continue conducting its Phase 3 clinical trial of PXT3003 as a treatment for the neurodegenerative disease Charcot-Marie-Tooth type 1A (CMT1A). It was the second safety evaluation that the Independent Data Safety Monitoring Board had completed. The therapy passed the first…
Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The trial will be conducted in the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic. Verona expects to start…
The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…
Get regular updates to your inbox.